NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.19 -0.61 (-0.76%) GOLD FUTURES
2,422.70 -15.80 (-0.65%) DOW
39,835.84 +29.07 (+0.07%) Bitcoin GBP
54,843.49 +984.66 (+1.83%)
MorphoSys AG (MOR.F)
| Previous close | 68.45 |
| Open | 68.15 |
| Bid | 68.00 x 90000 |
| Ask | 68.05 x 90000 |
| Day's range | 68.15 - 68.20 |
| 52-week range | 14.93 - 70.15 |
| Volume | |
| Avg. volume | 877 |
| Market cap | 2.57B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
MorphoSys AG Reports First Quarter 2024 Financial Results
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
- Business Wire
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
PLANEGG/MUNICH, Germany, April 11, 2024--The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as "Novartis"), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total e
- Business Wire
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PLANEGG/MUNICH, Germany, March 13, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.
